A pilot study on the neurocognitive effect of sorafenib on patients with desmoid tumours: the SORA-COG study.

IF 1.2 Q4 ONCOLOGY

ecancermedicalscience Pub Date : 2025-03-13 eCollection Date: 2025-01-01 DOI:10.3332/ecancer.2025.1871

Kamboji Sharanya, Lulu Abdul Khader, Fathima Shahama Oliyath Vazhayil, Ghazal Tansir, Vaishnavi Vishwas, Simran Kaur, Sameer Rastogi, Ratna Sharma

{"title":"A pilot study on the neurocognitive effect of sorafenib on patients with desmoid tumours: the SORA-COG study.","authors":"Kamboji Sharanya, Lulu Abdul Khader, Fathima Shahama Oliyath Vazhayil, Ghazal Tansir, Vaishnavi Vishwas, Simran Kaur, Sameer Rastogi, Ratna Sharma","doi":"10.3332/ecancer.2025.1871","DOIUrl":null,"url":null,"abstract":"Introduction: Sorafenib is a multikinase tyrosine kinase inhibitor whose prolonged use may lead to cognitive impairment due to inhibition of angiogenesis. However, data on its impact on neurocognitive function in desmoid tumours (DTs) is lacking.Methods: We conducted a cross-sectional study enrolling 50 participants including 30 with DT on sorafenib (Group 1), 10 treatment-naive patients with DT (Group 2) and 10 healthy controls (Group 3). Questionnaire-based assessment was done using appearance anxiety inventory, Depression anxiety and stress questionnaire-21 (DASS-21), Hindi mental status examination (HMSE) and computer-based Cambridge neuropsychological test automated battery (CANTAB) neuropsychological tests. Statistical analysis was performed using GraphPad Prism software version 10 and individual groups were compared using Kruskal-Wallis test with p value of <0.05 considered significant.Results: 50 participants had a median age of 29.91 years (25%-75% CI: 27.05-32.77 years), female predominance (n = 26, 52%), median duration of sorafenib 18.1 months (range: 6-60) at a median dose of 241.17 mg (range: 200-400). There was a statistically significant difference in anxiety (p = 0.0127) between Groups 1 (patients on sorafenib) and 3 (healthy controls), while other objective cognitive and neuropsychological parameters were comparable. There was a significant positive correlation between sorafenib duration and anxiety (p = 0.026) by DASS21, and a negative correlation between HMSE and mean five choice reaction time (p = 0.04).Conclusion: This is the first study to examine the neurocognitive effects of sorafenib in patients with DT. We exhibit significantly higher anxiety in patients with DT on sorafenib as compared to healthy controls. There was a significant correlation noted between anxiety and treatment duration. We propose further longitudinal studies to assess the effect of sorafenib in DT.","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1871"},"PeriodicalIF":1.2000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146563/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ecancermedicalscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3332/ecancer.2025.1871","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Sorafenib is a multikinase tyrosine kinase inhibitor whose prolonged use may lead to cognitive impairment due to inhibition of angiogenesis. However, data on its impact on neurocognitive function in desmoid tumours (DTs) is lacking.

Methods: We conducted a cross-sectional study enrolling 50 participants including 30 with DT on sorafenib (Group 1), 10 treatment-naive patients with DT (Group 2) and 10 healthy controls (Group 3). Questionnaire-based assessment was done using appearance anxiety inventory, Depression anxiety and stress questionnaire-21 (DASS-21), Hindi mental status examination (HMSE) and computer-based Cambridge neuropsychological test automated battery (CANTAB) neuropsychological tests. Statistical analysis was performed using GraphPad Prism software version 10 and individual groups were compared using Kruskal-Wallis test with p value of <0.05 considered significant.

Results: 50 participants had a median age of 29.91 years (25%-75% CI: 27.05-32.77 years), female predominance (n = 26, 52%), median duration of sorafenib 18.1 months (range: 6-60) at a median dose of 241.17 mg (range: 200-400). There was a statistically significant difference in anxiety (p = 0.0127) between Groups 1 (patients on sorafenib) and 3 (healthy controls), while other objective cognitive and neuropsychological parameters were comparable. There was a significant positive correlation between sorafenib duration and anxiety (p = 0.026) by DASS21, and a negative correlation between HMSE and mean five choice reaction time (p = 0.04).

Conclusion: This is the first study to examine the neurocognitive effects of sorafenib in patients with DT. We exhibit significantly higher anxiety in patients with DT on sorafenib as compared to healthy controls. There was a significant correlation noted between anxiety and treatment duration. We propose further longitudinal studies to assess the effect of sorafenib in DT.

查看原文本刊更多论文

索拉非尼对硬纤维瘤患者神经认知作用的初步研究：SORA-COG研究。

索拉非尼是一种多激酶酪氨酸激酶抑制剂，长期使用可能由于抑制血管生成而导致认知障碍。然而，缺乏其对硬纤维瘤（DTs）神经认知功能影响的数据。方法：我们进行了一项横断面研究，纳入了50名参与者，其中30名接受索拉非尼治疗的DT患者（1组），10名首次治疗的DT患者（2组）和10名健康对照（3组）。采用外表焦虑量表、抑郁焦虑和压力问卷-21 （DASS-21）、印度精神状态检查（HMSE）和基于计算机的剑桥神经心理测试自动电池（CANTAB）神经心理测试进行问卷评估。采用GraphPad Prism软件版本10进行统计分析，各组采用Kruskal-Wallis检验进行比较，p值为：结果：50名参与者中位年龄为29.91岁（25%-75% CI: 27.05-32.77年），女性占多数（n = 26, 52%），索拉非尼中位持续时间为18.1个月（范围：6-60），中位剂量为241.17 mg（范围：200-400）。第1组（索拉非尼组）和第3组（健康对照组）在焦虑方面的差异有统计学意义（p = 0.0127），而其他客观认知和神经心理学参数具有可比性。DASS21结果显示，索拉非尼持续时间与焦虑呈显著正相关（p = 0.026）， HMSE与平均五项选择反应时间呈显著负相关（p = 0.04）。结论：这是第一个研究索拉非尼对DT患者神经认知影响的研究。我们发现，与健康对照组相比，服用索拉非尼的DT患者的焦虑程度明显更高。焦虑与治疗持续时间之间存在显著相关性。我们建议进一步的纵向研究来评估索拉非尼对DT的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊